Physician profile
Gregory A Ruff
NPI 1548249642
$6,200.66
in general payments reported to CMS, 2019-2025
14 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $68.19 · 2022: $16.93 · 2023: $3,380 · 2024: $1,422 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,062 · Consulting Fee: $2,100 · Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,062.31 |
| Consulting Fee | $2,100.00 |
| Food and Beverage | $698.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $5,296.36 | 2023-2025 | Galaxy |
| Astrazeneca Pharmaceuticals Lp | $580.63 | 2019-2024 | Tagrisso |
| Genentech USA, INC. | $47.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.80 | 2019-2025 | Jascayd |
| Actelion Pharmaceuticals US, INC. | $40.75 | 2019 | |
| Glaxosmithkline, LLC. | $33.72 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $25.00 | 2020 | |
| Abbvie INC. | $21.71 | 2025 | |
| Advanced Respiratory, INC | $21.08 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.77 | 2019 | |
| Merck Sharp & Dohme LLC | $17.78 | 2019 | |
| Shire North American Group INC | $17.55 | 2019 | |
| Harmony Biosciences LLC | $16.93 | 2022 | |
| Philips North America LLC | $16.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.